RXST SECURITIES NEWS: Did RxSight, Inc. (NASDAQ:RXST) Commit Securities Fraud? Contact BFA Law about its Investigation into the Company

Core Viewpoint - RxSight, Inc. is under investigation for potential violations of federal securities laws following a significant decline in its stock price due to revenue forecast cuts related to a slowdown in product utilization [1][4][5]. Company Overview - RxSight specializes in manufacturing and selling light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [2]. Financial Performance - The company previously reported strong sales for its LAL and Light Delivery Device (LDD), but began experiencing a slowdown in LAL utilization noted in 2024 [3]. - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38% from $26.12 to $16.21 per share [4]. - A further revenue forecast cut occurred on July 8, 2025, attributed to slower LAL utilization, resulting in another 38% decline in stock price from $12.79 to $7.95 per share [5].